Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Salvi

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Current Opinion in Endocrinology, Diabetes, and Obesity|August 9, 2014
Immunotherapy for Graves' ophthalmopathyMario Salvi
European Thyroid Journal|February 2, 2026
What has changed in Thyroid Eye Disease in the last five years (2020-2025)Mario Salvi
Nature Reviews. Endocrinology|September 29, 2018
Step-down steroid-sparing therapy in active thyroid eye diseaseMario Salvi
Eye (London, England)|December 6, 2018
B cells in Graves' Orbitopathy: more than just a source of antibodies?Mario Salvi, Danila Covelli
Clinical Endocrinology|December 15, 2018
Combined immunosuppressants and less steroids in active graves' orbitopathy?Mario Salvi, Danila Covelli
European Journal of Endocrinology|October 21, 2016
MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trialsMarius N Stan, Mario Salvi
European Journal of Endocrinology|April 2, 2016
THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathyIrene Campi, Guia Vannucchi, Mario Salvi
The Journal of Clinical Endocrinology and Metabolism|September 7, 2013
Potential utility of rituximab for Graves' orbitopathyMario Salvi, Guia Vannucchi, Paolo Beck-Peccoz
The Journal of Clinical Endocrinology and Metabolism|November 8, 2022
Future Projections in Thyroid Eye DiseaseGiuseppe Barbesino, Mario Salvi, Suzanne K Freitag
Thyroid : Official Journal of the American Thyroid Association|April 16, 2002
Prediction of the progression of thyroid-associated ophthalmopathy at first ophthalmologic examination: use of a neural networkMario Salvi, Davide Dazzi, Isabella Pellistri, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Current Opinion in Endocrinology, Diabetes, and Obesity|August 9, 2014
Immunotherapy for Graves' ophthalmopathyMario Salvi
European Thyroid Journal|February 2, 2026
What has changed in Thyroid Eye Disease in the last five years (2020-2025)Mario Salvi
Nature Reviews. Endocrinology|September 29, 2018
Step-down steroid-sparing therapy in active thyroid eye diseaseMario Salvi
Eye (London, England)|December 6, 2018
B cells in Graves' Orbitopathy: more than just a source of antibodies?Mario Salvi, Danila Covelli
Clinical Endocrinology|December 15, 2018
Combined immunosuppressants and less steroids in active graves' orbitopathy?Mario Salvi, Danila Covelli
European Journal of Endocrinology|October 21, 2016
MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trialsMarius N Stan, Mario Salvi
European Journal of Endocrinology|April 2, 2016
THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathyIrene Campi, Guia Vannucchi, Mario Salvi
The Journal of Clinical Endocrinology and Metabolism|September 7, 2013
Potential utility of rituximab for Graves' orbitopathyMario Salvi, Guia Vannucchi, Paolo Beck-Peccoz
The Journal of Clinical Endocrinology and Metabolism|November 8, 2022
Future Projections in Thyroid Eye DiseaseGiuseppe Barbesino, Mario Salvi, Suzanne K Freitag
Thyroid : Official Journal of the American Thyroid Association|April 16, 2002
Prediction of the progression of thyroid-associated ophthalmopathy at first ophthalmologic examination: use of a neural networkMario Salvi, Davide Dazzi, Isabella Pellistri, et al.
Pageof 6